Article Commentary: Transmitted Resistance to HIV Integrase Strand-Transfer Inhibitors: Right on Schedule | Zendy

Christopher B. Hurt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Article Commentary: Transmitted Resistance to HIV Integrase Strand-Transfer Inhibitors: Right on Schedule

Author(s) -

Christopher B. Hurt

Publication year - 2011

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp1750

Subject(s) - integrase , integrase inhibitor , virology , reverse transcriptase , reverse transcriptase inhibitor , protease inhibitor (pharmacology) , hiv drug resistance , human immunodeficiency virus (hiv) , drug resistance , lentivirus , medicine , viral load , antiretroviral therapy , biology , viral disease , genetics , polymerase chain reaction , gene

Transmitted drug resistance (TDR), the primary acquisition of an HIV variant already resistant to antiretrovirals, affects approximately 15% of all new infections in the United States. Historically, from the time initial agents in the reverse transcriptase, protease and entry inhibitor classes were introduced, it took 3-5 years before the first case reports of TDR appeared. With the description of the first two cases of transmitted integrase stand-transfer inhibitor resistance, it is only a matter of time before the prevalence of TDR affecting this newest antiretroviral class reaches a level warranting baseline resistance testing for all patients entering care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research